CAFs can additionally increase the expression of PD-L1 on tumor cell surfaces by expressing CXCL5, which engages CXCR2 on tumor cells and upregulates PD-L1 by activating PI3K/AKT signaling (Li Z. et al., 2019). The gene discussed is CXCL5; the disease is neoplasm.